文献速递消化系统肿瘤

早期肿瘤退缩与反应深度对HER-2阳性晚期胃癌一线曲妥珠单抗联合化疗预后与疗效的关系

[Relationship of early tumor shrinkage and depth of response with the prognosis and treatment effect of trastuzumab combined with chemotherapy as first-line treatment in advanced gastric cancer patients with epidermal growth factor receptor 2 positive].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该研究回顾性分析23例HER-2阳性转移性胃腺癌患者,接受曲妥珠单抗联合化疗一线治疗。结果显示ETS≥20%和DpR≥15%患者的中位PFS和OS均显著优于低于阈值者,ETS是PFS的独立影响因素,提示ETS和DpR可能预测疗效与预后。

要点

  • ETS≥20%患者中位PFS 13.0个月、OS 26.8个月,显著优于ETS<20%者。
  • DpR≥15%患者中位PFS 13.0个月、OS 26.8个月,显著优于DpR<15%者。
  • 多因素分析显示ETS是PFS的独立影响因素(P=0.030)。

核心结论

  • ETS和DpR可能有效预测曲妥珠单抗联合化疗一线治疗HER-2阳性晚期胃癌的疗效和预后。

研究设计与样本

  • 回顾性分析2008年1月1日至2017年12月31日浙江大学医学院附属第二医院23例组织学明确胃腺癌、影像学证实转移性胃癌患者的临床病理资料。
  • 采用Kaplan-Meier法和Log rank检验进行生存分析,Cox回归分析影响预后的因素。

主要发现

  • 23例患者客观有效率为43.5%,疾病控制率为82.6%。
  • ETS≥20%和ETS<20%患者的中位PFS分别为13.0和4.5个月,差异有统计学意义(P<0.001)。
  • ETS≥20%和ETS<20%患者的中位OS分别为26.8和10.1个月,差异有统计学意义(P<0.001)。
  • DpR≥15%和DpR<15%患者的中位PFS分别为13.0和4.5个月,差异有统计学意义(P=0.001)。
  • DpR≥15%和DpR<15%患者的中位OS分别为26.8和9.5个月,差异有统计学意义(P<0.001)。

关键数值与推荐

  • 多因素分析显示ETS为影响患者PFS的独立因素(P=0.030)。
  • 肿瘤部位和美国东部肿瘤协作组评分为影响患者OS的独立因素(均P<0.05)。

临床怎么用

  • 在HER-2阳性晚期胃癌一线曲妥珠单抗联合化疗中,可关注早期肿瘤退缩和反应深度以辅助评估疗效与预后。

局限性

  • 本研究为单中心回顾性分析,样本量23例,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the relationship of early tumor shrinkage (ETS) and depth of response (DpR) with the prognosis and treatment effect of trastuzumab combined with chemotherapy as first-line treatment in advanced gastric cancer with epidermal growth factor receptor 2 (HER-2) positive. Methods: We retrospectively analyzed the clinical and pathological data of 23 patients with metastatic gastric adenocarcinoma diagnosed by imaging in The Second Affiliated Hospital of Zhejiang University School of Medicine from January 1st, 2008 to December 31th, 2017. Kaplan-Meier method and the log-rank test were used for the survival analysis. Cox regression was used to analyze the factors associated with prognosis. Results: The objective response rate (ORR) of the 23 patients was 43.5% and the disease control rate (DCR) was 82.6%. Univariate analysis showed the median progress-free survival (mPFS) of ETS≥20% and ETS<20% were 13.0 months and 4.5 months, respectively, with statistical significance (P<0.001). The median overall survival (mOS) of ETS≥20% and ETS<20% were 26.8 months and 10.1 months, respectively, with statistical significance (P<0.001). The median progress-free survival (mPFS) of DpR≥15% and DpR<15% were 13.0 months and 4.5 months, respectively, with statistical significance (P=0.001). The median overall survival (mOS) of DpR≥15% and DpR<15% were 26.8 months and 9.5 months, respectively, with statistical significance (P<0.001). Multivariable Cox regression analysis revealed ETS was an independent factor of PFS (P=0.030), tumor site and Eastern Cooperative Oncology Group (ECOG) score were independent factors of OS (P<0.05). Conclusion: ETS and DpR might be used to predict the treatment efficacy and prognosis of trastuzumab combined with chemotherapy as the first-line treatment of HER-2 positive gastric cancer. 目的: 探讨早期肿瘤退缩(ETS)和肿瘤反应深度(DpR)与曲妥珠单抗联合化疗一线治疗人表皮生长因子受体2(HER-2)阳性晚期胃癌患者的疗效及预后的关系。 方法: 回顾性分析2008年1月1日至2017年12月31日间就诊于浙江大学医学院附属第二医院的23例组织学明确为胃腺癌、影像学证实为转移性胃癌患者的临床病理资料。采用Kaplan-Meier法和Log rank检验进行生存分析,采用Cox回归分析对可能影响患者预后的因素进行分析。 结果: 23例患者中,客观有效率为43.5%,疾病控制率为82.6%。单因素分析显示,ETS≥20%和ETS<20%患者的中位无进展生存时间(PFS)分别为13.0和4.5个月,差异有统计学意义(P<0.001);ETS≥20%和ETS<20%患者中位总生存时间(OS)分别为26.8和10.1个月,差异有统计学意义(P<0.001)。DpR≥15%和DpR<15%患者的中位PFS分别为13.0和4.5个月,差异有统计学意义(P=0.001);DpR≥15%和DpR<15%患者的中位OS分别为26.8和9.5个月,差异有统计学意义(P<0.001)。多因素分析显示,ETS为影响患者PFS的独立因素(P=0.030),肿瘤部位和美国东部肿瘤协作组评分为影响患者OS的独立因素(均P<0.05)。 结论: ETS和DpR可能有效预测曲妥珠单抗联合化疗一线治疗HER-2阳性晚期胃癌的疗效和预后。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhu N, Chen JQ, Yang MY, et al. [Relationship of early tumor shrinkage and depth of response with the prognosis and treatment effect of trastuzumab combined with chemotherapy as first-line treatment in advanced gastric cancer patients with epidermal growth factor receptor 2 positive]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 33113630. doi:10.3760/cma.j.cn112152-20190213-00082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。